Published in Chromosoma on August 12, 2014
Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target. Oncotarget (2015) 0.80
A small molecule inhibitor of WEE1, AZD1775, synergizes with olaparib by impairing homologous recombination and enhancing DNA damage and apoptosis in acute leukemia. Mol Cancer Ther (2017) 0.76
RECQ helicases are deregulated in hematological malignancies in association with a prognostic value. Biomark Res (2016) 0.76
A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clin Cancer Res (2016) 0.76
High expression of S100A8 gene is associated with drug resistance to etoposide and poor prognosis in acute myeloid leukemia through influencing the apoptosis pathway. Onco Targets Ther (2016) 0.75
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13
The DNA-damage response in human biology and disease. Nature (2009) 17.86
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet (2001) 10.77
XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev (1999) 9.50
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol (2007) 8.10
Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature (2007) 7.72
Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature (2004) 7.21
DNA repair pathways as targets for cancer therapy. Nat Rev Cancer (2008) 6.69
Oncogenic transcription factors in the human acute leukemias. Science (1997) 6.45
The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol (2006) 6.16
hDOT1L links histone methylation to leukemogenesis. Cell (2005) 5.83
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 5.72
Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 5.63
Base-excision repair of oxidative DNA damage. Nature (2007) 5.44
Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol (2010) 5.35
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 5.30
Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell (1996) 5.29
p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell (2007) 4.01
The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer (2003) 3.97
Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature (2009) 3.90
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood (2007) 3.60
Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature (2009) 3.37
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood (2011) 3.32
How nucleotide excision repair protects against cancer. Nat Rev Cancer (2001) 3.29
Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol (1993) 3.17
Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell (2007) 3.16
DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med (2005) 3.06
PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J (2009) 2.99
Mouse models of human AML accurately predict chemotherapy response. Genes Dev (2009) 2.75
Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res (1998) 2.63
PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J Biol Chem (2007) 2.62
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell (2012) 2.26
DNA ligase III promotes alternative nonhomologous end-joining during chromosomal translocation formation. PLoS Genet (2011) 2.22
Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol (2007) 2.14
End-joining, translocations and cancer. Nat Rev Cancer (2013) 2.13
Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest (2003) 2.12
BRCA2-dependent and independent formation of RAD51 nuclear foci. Oncogene (2003) 2.03
A role for PML and the nuclear body in genomic stability. Oncogene (1999) 1.97
An essential role for CtIP in chromosomal translocation formation through an alternative end-joining pathway. Nat Struct Mol Biol (2010) 1.92
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood (2011) 1.88
EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut (2011) 1.87
Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. J Biol Chem (2007) 1.80
Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood (2008) 1.80
The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med (2002) 1.75
DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell (2011) 1.67
Homologous pairing promoted by the human Rad52 protein. J Biol Chem (2001) 1.64
The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev (1996) 1.63
DNA damage response in adult stem cells: pathways and consequences. Nat Rev Mol Cell Biol (2011) 1.57
Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia. Cancer Cell (2006) 1.53
Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci U S A (2012) 1.52
A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2001) 1.51
Forced homo-oligomerization of RARalpha leads to transformation of primary hematopoietic cells. Cancer Cell (2006) 1.48
Increased error-prone non homologous DNA end-joining--a proposed mechanism of chromosomal instability in Bloom's syndrome. Oncogene (2002) 1.47
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood (2013) 1.46
Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation. Cancer Cell (2007) 1.44
Do reactive oxygen species play a role in myeloid leukemias? Blood (2011) 1.43
Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene (2001) 1.41
Inhibition of Chk1 by activated PKB/Akt. Cell Cycle (2004) 1.38
Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Res (2007) 1.36
MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. Exp Hematol (2010) 1.35
Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett (2008) 1.33
Direct involvement of the small GTPase Rac in activation of the superoxide-producing NADPH oxidase Nox1. J Biol Chem (2006) 1.33
Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell (2014) 1.30
Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity. Proc Natl Acad Sci U S A (2012) 1.29
Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood (2007) 1.28
Spontaneous DNA damage, genome instability, and cancer--when DNA replication escapes control. Cell (2001) 1.28
Characterisation of the promoter region of the human DNA-repair gene Rad51. Eur J Gynaecol Oncol (2005) 1.27
Overexpression of human RAD51 and RAD52 reduces double-strand break-induced homologous recombination in mammalian cells. Nucleic Acids Res (2001) 1.26
Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation. Cell Death Differ (2014) 1.25
The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation. Genes Dev (2009) 1.24
Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage. J Biol Chem (2005) 1.23
The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. Leukemia (2009) 1.22
Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1. Cell Rep (2013) 1.22
Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res (2004) 1.20
FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). Blood (2004) 1.19
p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. Blood (2007) 1.18
Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood (1999) 1.18
Ras-induced reactive oxygen species promote growth factor-independent proliferation in human CD34+ hematopoietic progenitor cells. Blood (2009) 1.18
The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Blood (2007) 1.17
Oncogenic K-ras cooperates with PML-RAR alpha to induce an acute promyelocytic leukemia-like disease. Blood (2006) 1.17
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood (2013) 1.16
The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood (2002) 1.16
Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J (2004) 1.16
Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia. Proc Natl Acad Sci U S A (2002) 1.16
Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks. Oncogene (2002) 1.15
From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair (Amst) (2003) 1.13
Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer (2005) 1.11
NHEJ and its backup pathways in chromosomal translocations. Nat Struct Mol Biol (2010) 1.11
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther (2009) 1.11
Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br J Haematol (2001) 1.10
Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood (2004) 1.09
Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins. Cancer Res (2003) 1.07
Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy. Blood (2010) 1.07
Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer (2002) 1.06
Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev (2007) 4.07
Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol (2007) 2.14
β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell (2010) 1.65
Forced homo-oligomerization of RARalpha leads to transformation of primary hematopoietic cells. Cancer Cell (2006) 1.48
Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation. Cancer Cell (2007) 1.44
The histone demethylase PHF8 governs retinoic acid response in acute promyelocytic leukemia. Cancer Cell (2013) 1.38
Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell (2011) 1.33
SnapShot: Acute myeloid leukemia. Cancer Cell (2012) 0.96
Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes. Proc Natl Acad Sci U S A (2009) 0.96
Transcriptional and epigenetic networks in haematological malignancy. FEBS Lett (2011) 0.91
Interplay between Homeobox proteins and Polycomb repressive complexes in p16INK⁴a regulation. EMBO J (2013) 0.89
Overcoming treatment resistance in acute promyelocytic leukemia and beyond. Oncotarget (2013) 0.86
Identification and characterization of hematopoietic stem and progenitor cell populations in mouse bone marrow by flow cytometry. Methods Mol Biol (2009) 0.86
Functions of flt3 in zebrafish hematopoiesis and its relevance to human acute myeloid leukemia. Blood (2014) 0.85
Leukemic transformation by the APL fusion protein PRKAR1A-RAR{alpha} critically depends on recruitment of RXR{alpha}. Blood (2009) 0.83
Discovery of novel transcriptional and epigenetic targets in APL by global ChIP analyses: Emerging opportunity and challenge. Cancer Cell (2010) 0.78
Reconstructing the disease model and epigenetic networks for MLL-AF4 leukemia. Cancer Cell (2008) 0.78
Retroviral/Lentiviral transduction and transformation assay. Methods Mol Biol (2009) 0.78
A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia. PLoS One (2013) 0.78
Mixed lineage leukemia protein in normal and leukemic stem cells. Exp Biol Med (Maywood) (2013) 0.77
The role of CBFbeta in AML1-ETO's activity. Blood (2010) 0.77
Sox4you: a new player in C/EBPα leukemia. Cancer Cell (2013) 0.77
Collaboration between PcG proteins and MLL fusions in Leukemogenesis: an emerging paradigm. Cancer Cell (2011) 0.76
Linking MLL Leukemia with Integrin Signaling. Cancer Cell (2013) 0.75